Dehong Yu

TL;DR: A drug delivery system (DDS), nanoparticles conjugated with K237-(HTMYYHHYQHHL) peptides for tumor neovasculature targeting drug delivery, which offers a new strategy for paclitaxel chemotherapy application and it could also be used to carry other chemotherapeutic drugs, genes, and proteins with antiangiogenic activity for antiangsiogenic cancer therapy.

TL;DR: The specific apoptotic mechanism of DCA as distinguished from the cisplatin may be partly responsible for the synergy and further in vivo study on combination chemotherapy of the two agents in cervical cancer xenografts in mice is warranted.

TL;DR: The results suggest that the nanoparticles targeting drug to tumor neovasculature may be a promising strategy for the treatment of multidrug resistant cancer.

TL;DR: The focus of this review is to identify candidate agents as novel molecular targets, drug administration routes, delivery systems, and dosage schedules, and animal models of cisplatin ototoxicity that have been used to evaluate drug efficacy and side effect prevention.

TL;DR: F56-VCR-NP significantly prolonged the mouse survival with no obvious toxicity in the CT-26 lung metastasis mice model, and this pronounced antitumor effect was closely related with the decreased microvessel density in the metastases.